Legend Biotech Corp
9LB
Company Profile
Business description
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Contact
2101 Cottontail Lane
SomersetNJ08873
USAT: +1 737 317-5050
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2,900
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,726.20 | 27.10 | -0.31% |
| CAC 40 | 7,967.93 | 151.09 | -1.86% |
| DAX 40 | 23,180.53 | 409.99 | -1.74% |
| Dow JONES (US) | 46,091.74 | 498.50 | -1.07% |
| FTSE 100 | 9,552.30 | 123.13 | -1.27% |
| HKSE | 25,813.40 | 116.63 | -0.45% |
| NASDAQ | 22,432.85 | 275.23 | -1.21% |
| Nikkei 225 | 48,688.15 | 14.83 | -0.03% |
| NZX 50 Index | 13,326.90 | 15.92 | -0.12% |
| S&P 500 | 6,617.32 | 55.09 | -0.83% |
| S&P/ASX 200 | 8,454.30 | 29.20 | -0.34% |
| SSE Composite Index | 3,936.76 | 3.05 | -0.08% |